Key Takeaways

Wegovy users had a 57% greater reduction in heart attack, stroke and death risk compared to tirzepatide users

The study analyzed data from 21,000 patients with obesity and heart disease

Findings suggest GLP-1 drugs may offer different levels of heart protection

WEDNESDAY, Sept. 3, 2025 (HealthDay News) — The weight-loss drug Wegovy may lower the risk of heart attack , stroke or death more than similar medications, according to new research from its maker, Novo Nordisk .

In a study of more than 21,000 patients with obesity and heart disease but no diabetes, those taking Wegovy — which contains the active ingredient semaglutide — saw a 57% greater reduction in heart-related risks compared to people taking tirzepatide, the ingredient in Eli Lilly’s weight-loss dru

See Full Page